Compositions and methods for inducing immune tolerance
AssigneeThe University of Chicago
InventorsAaron ESSER-KAHN, Peter DEAK
Life of this patent
Estimating the term…
Abstract
Aspects of the present disclosure are directed to methods and compositions for generation of antigen-specific regulatory T cells. Certain aspects relate to methods and compositions for generating tolerogenic antigen presenting cells, including tolerogenic dendritic cells. The present disclosure includes compositions, including nanocarrier compositions, comprising TLR agonists, and immunosuppressive agents and optionally an antigen. Also disclosed are methods for use of such compositions in generation of tolerogenic antigen presenting cells and treatment of certain conditions, including autoimmune and inflammatory conditions.
Claims202
A composition comprising (a) a TLR agonist;
- and (b) one or more immunosuppressive agents.
A method for treating a subject for cancer or an autoimmune or inflammatory condition, the method comprising administering to the subject an effective amount of
- (i) one or more TLR agonist;
- and
- (ii) one or more immunosuppressive agents.
A method for generating tolerogenic dendritic cells, the method comprising providing, to a population of dendritic cells or dendritic cell precursors:
- (a) one or more TLR agonists;
- and
- (b) one or more immunosuppressive agents.
A liposome comprising (a) an antigen associated with multiple sclerosis;
- (b) flagellin conjugated to an exterior surface of the liposome;
- (c) dexamethasone, (d) simvastatin, and (e) SC 514.
A liposome comprising (a) an antigen associated with multiple sclerosis;
- (b) a CpG oligonucleotide conjugated to an exterior surface of the liposome;
- (c) dexamethasone, (d) simvastatin, and (e) SC 514.
A method for treating a subject for multiple sclerosis, the method comprising administering to the subject an effective amount of a composition comprising:
- a liposome comprising:
- (i) an antigen associated with multiple sclerosis;
- and
- (ii) the combination of one of:
- (a) flagellin, dexamethasone, simvastatin, and SC 514;
- (b) a CpG oligonucleotide, dexamethasone, simvastatin, and SC 514;
- (c) cucurbitacin and LPS;
- (d) costunolide and Pam2CSK4;
- (e) MLN120B and Pam2CSK4;
- (f) parthenolide and Pam2CSK4;
- (g) peficitinib and Pam2CSK4;
- (h) oclacitinib maleate and R848;
- (i) AD80 and Pam2CSK4;
- (j) cucurbitacin B and R848;
- (k) CEP-33779 and R848;
- or
- (l) dehydrocostus lactone and R848.
A method for treating or preventing graft versus host disease or graft rejection in a subject, the method comprising administering to the subject an effective amount of a composition comprising:
- a liposome comprising the combination of one of:
- (a) flagellin, dexamethasone, simvastatin, and SC 514;
- (b) a CpG oligonucleotide, dexamethasone, simvastatin, and SC 514;
- (c) cucurbitacin and LPS;
- (d) costunolide and Pam2CSK4;
- (e) MLN120B and Pam2CSK4;
- (f) parthenolide and Pam2CSK4;
- (g) peficitinib and Pam2CSK4;
- (h) oclacitinib maleate and R848;
- (i) AD80 and Pam2CSK4;
- (j) cucurbitacin B and R848;
- (k) CEP-33779 and R848;
- or
- (l) dehydrocostus lactone and R848.
Dependencies are inferred from the claim text.